Alpha Tau Medical Ltd. (DRTS)
NASDAQ (CM) NASDAQ (CM) Primary 
Alpha Tau Medical: A Lot Of Shots On Goal
Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology overcomes prior range limitations and shows high response rates in multiple indications. This month's recent Tolmar partnership brings $35M in upfront capital and potential milestones, supporting DRTS's cash runway through 2027 amid ongoing trials.
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Medical NASDAQ: DRTS outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company's most important trials are “coming to a head” over the coming months.
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical NASDAQ: DRTS presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial.
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of “Hold” from Brokerages
Shares of Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a
Alpha Tau Medical: 2026 Is The Breakthrough Year
Alpha Tau Medical pioneers localized alpha particle radiation for solid tumors, with its Alpha DaRT technology showing broad applicability and strong early efficacy. 2026 is pivotal for DRTS, with multiple clinical trial readouts expected in cSCC, pancreatic, GBM, and prostate cancers, potentially transforming its market standing. Despite a $42.3M operating loss in 2025 and no revenue, DRTS has about five to six quarters of cash, but dilution risk remains high.
New Strong Sell Stocks for January 27th
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026
Alpha Tau Medical is positioned for major catalysts in 2026, with its differentiated, tumor-agnostic Alpha DaRT technology gaining visibility and momentum. Pancreatic cancer and GBM readouts expected in 2H26 have the potential to be inflection points. At ~$550M market cap, a strong cash position, and multiple upcoming readouts, DRTS offers attractive upside as it approaches proof-of-concept in high-impact oncology indications.
